Navigating Japan’s 2026 Markets: Pharma Deals, MUFG’s Asian Push and Bond Volatility
A shrinking drug pipeline, fierce competition for Asian transaction banking, and the slowest corporate bond market since 2023. For Japanese markets in Q2 2026, domestic pressures and Middle East volatility are creating significant headwinds—but are also driving pushes for global expansion.
From Tanabe Pharma’s AI-driven licensing hunt to MUFG’s bid for regional dominance, here is how Japan’s major players are shifting their strategies.
Table of Contents:
- Pharma Sector: Prioritizing Global Licensing and Rare Diseases
- Transaction Banking: MUFG Expands Asian Footprint
- Corporate Bonds: Market Faces Geopolitical and Rate Volatility
Pharma Sector: Prioritizing Global Licensing and Rare Diseases
Bloomberg reported in late March that Bain Capital-owned Tanabe Pharma was on the hunt for licensing deals abroad to bring medicines into Japan. The report noted that a combination of unmet patient demand and the easing of regulations would fuel growth.
“We are facing a lack of a pipeline so in the short term, we have to do a lot of licensing,” Chief Executive Officer Akihisa Harada told Bloomberg. “We set up a US team to actively search for licensing opportunities, not only from the US but also from China and Europe.”
That US team of about eight people is being led by a former McKinsey partner, working alongside the existing Japan team. They are focused heavily on global therapies, particularly in rare diseases such as inflammation immunology, oncology and neuroscience. Two deals are already in the works for 2026.
Costa Saroukos, Takeda Pharmaceutical’s former chief financial officer who joined Tanabe as chairman in September 2025, noted that the company is adopting AI to boost productivity and streamlining operations. “We are doubling down on investing in Japan for the Japan market,” Saroukos said.
However, global drugmakers face a unique set of challenges in the Japanese market:
- Drug Lag: As of March 2023, 143 drugs approved in the U.S. and Europe had yet to win Japanese approval. Many of these are startup-driven orphan drugs (therapies for rare medical conditions) and pediatric treatments.
- Pricing Pressure: To contain costs for a rapidly aging population, Japan exerts heavy drug-pricing pressure. Global drugmakers warn this could undermine R&D returns and discourage the introduction of innovative therapies.
- Price Gap: While US drug prices average 347% of Japanese levels, the gap is narrowing for newer therapies. For example, Chugai Pharmaceutical’s rare disease treatment Elevidys was priced at about 300 million yen ($1.9 million) in Japan in February, compared with $3.2 million to $3.8 million in the US
Still, interest from drugmakers remains strong for rare disease treatments, where Harada noted pricing remains relatively favorable.
Transaction Banking: MUFG Expands Asian Footprint
On another front, Mitsubishi UFJ Financial Group (MUFG) is trying to boost its transaction banking business by expanding domestic money transfer services across Asia and hiring new talent.
Banks compete intensely for transaction banking revenue because it provides a stable, low-cost source of funding via the cash clients keep for daily transfers. Global transaction banking generated nearly $1.3 trillion in revenue in 2024—roughly half of the wholesale banking revenue pool, according to a September 2025 McKinsey report.
Japan’s largest lender has historically trailed global behemoths like JPMorgan Chase and HSBC Holdings. Now, MUFG aims to take the top spot in transaction banking in Asia from its current third position.
“While working to close the gap with various foreign banks, we are positioning ourselves to move into a new area,” said Masahiro Matsumoto, global head of transaction banking at MUFG Bank, to Bloomberg. He noted that competition for talent to fill new positions is intensifying.
MUFG has about 1,300 staff involved globally in transaction banking—services offered to companies for mundane tasks such as cash management, billing, payments and trade finance. The bank has a competitive advantage in Asia, holding significant stakes in banks in Vietnam and the Philippines, and owning local commercial lenders like Thailand’s Bank of Ayudhya.
Launching money transfer services in Thailand, Indonesia, the Philippines and Vietnam will allow MUFG customers to access domestic payment networks without opening local bank accounts. The bank hopes to attract local currency deposits from Japanese and multinational companies operating in Southeast Asia.
“It’s difficult to win competition against US banks in US markets,” Matsumoto said. “But US and European companies are expanding in Asia, where we have a strong chance.”
Corporate Bonds: Market Faces Geopolitical and Rate Volatility
Finally, the pipeline for Japanese corporate bonds is the slowest since 2023. Investors are contending with uncertainty surrounding the Middle East war, and the number of borrowers planning yen deals at the start of the new 2026 fiscal year is down about 60% from a year earlier.
This regional turbulence underscores how Japanese companies may struggle to rely on the credit market for stable funding, even after the record bond sales of the last financial year. Key factors driving this volatility include:
- Widening Credit Spreads: Heightened geopolitical tensions drove credit spreads up to around 46 basis points in early April, compared with 44.4 basis points just before the U.S. and Israeli attacks on Iran began on Feb. 28.
- Rising Yields: Benchmark 10-year Japanese government bond yields rose to 2.39% in March, the highest in almost three decades.
- Interest Rate Speculation: Overnight index swaps imply about a 70% chance of the Bank of Japan (BOJ) increasing rates later in April, adding severe rate volatility to an already pressured market.
Another factor making it difficult for corporate issuers to price bonds is the unprecedented, massive daily swings on Japanese deals that require a long marketing period.
“Volatility is high, and it is hard to tell how soon the Middle East situation will calm down, or how views on a BOJ rate hike will evolve,” said Kazuma Ogino, a senior credit analyst at Nomura Securities.
Despite these challenging headwinds and rising funding costs, Japan Post and eleven other issuers are still moving forward with planned bond sales in April and May.
